TOKYO
Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces the appointment of Mr Peter Bains as Representative Executive Officer and Chief Executive Officer (CEO) effective from June 24 2016 upon approval by the Board of Directors following Sosei Group’s Annual General Meeting. At the same time, Mr Shinichi Tamura, Sosei founder and Group Chairman, President and CEO, is appointed as Representative Executive Officer and Executive Chairman. Peter Bains will continue to report to Mr Shinichi Tamura.
|
1. |
The reason for appointment | ||
|
To further strengthen/develop the system of management to improve our corporate |
|||
| 2. | The name and title of Representative Executive Officer | ||
| Name: | Peter Bains | ||
| Title: | Representative Executive Officer and Chief Executive Officer (CEO) | ||
|
3. |
Brief summary of Peter Bains |
|||||
| Date of birth | Profile |
Ownership of |
||||
| July 26 1957 | March 1996: General Manager of SmithKline Beecham plc. (GlaxoSmithKline) | 0 | ||||
| January 2001: Senior Vice President, GlaxoSmithKline International Commercial Development | ||||||
| June 2009: Director of Peter Bains Consulting Limited. | ||||||
| January 2010: Non-executive Board Director at Syngene International Limited | ||||||
| June 2010: Non-executive Director at Sosei Group Corporation | ||||||
| February 2015: Director at Heptares Therapeutics Ltd. | ||||||
| February 2015: Executive Director and CEO at Syngene International Limited | ||||||
| April 2016:Representative Executive Officer and Chief Operating Officer at Sosei Group Corporation | ||||||
| 4. | Effective date | |
| As of June 24 2016 | ||
About Sosei
Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei have established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei have already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.
For further information about Sosei, please visit www.sosei.com/en.
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160624005208/en/
CONTACT
Enquiries:
Sosei Group Corporation
Tokyo Office
Harumi
BANSE, +81-(0)3-5210-3399
Investor Relations
hbanse@sosei.com
or
London
Office
Kathryn LYDON, +44-(0)20-7691-0983
Corporate
Communications
klydon@sosei.com
